Proven networking antioxidants
- Helps reduce inflammation and cellular damage that contributes to aging
- Superior protection over other antioxidant formulas
- A dynamic team of antioxidants which can “recycle” one another
$71.19 — or subscribe and save 20%
Out of stock
Antioxidants are nutrients found in all types of fruits and vegetables, plants, nuts and seeds. They help to protect the body from the damage caused by toxic molecules called free radicals. Free radicals play a role in the aging process and the development of most diseases including cataracts, heart disease, infertility, arthritis, abnormal cell development and many other chronic health conditions.
Antioxidants work by neutralizing free radicals before they can damage cells. They do this by stabilizing them but during this process, the antioxidants themselves become mild free radicals and must be “recycled” back to their original form to keep acting as antioxidant. Moreover, some antioxidants are more effective in certain locations in the body than others, meaning that you need to take the right ones for best results!
The vicious cycle of oxidation can be prevented through taking advantage of the unique complementary interactions of an elite antioxidant strike force: the Networking Antioxidants. There are five networking antioxidants: R (+)-lipoic acid, the vitamin E complex, vitamin C, coenzyme Q10, and glutathione (GSH). When taken together, these essential nutrients form a dynamic team of protectors which can “recycle” one another. By this process, networking antioxidants enhance and extend one another’s capacities.
Other antioxidants play a supporting role to the networking antioxidants. The best understood of these network-boosters are bioflavonoids and the mineral selenium. Among bioflavonoids, carnosic acid and resveratrol are particularly interesting. Carnosic acid is found in the herb rosemary while resveratrol comes from grapes. Selenium also supports the network by maintaining the body’s supply of two key enzymes.
AOR’s Antioxidant Synergy offers the most powerful combination of antioxidants to reduce inflammation and cellular damage that contribute to aging and chronic health conditions.
Antioxidant Synergy provides a research-backed combination of synergistic antioxidants for optimal health.
AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, nuts, peanuts, sesame seeds, sulphites, mustard, dairy, eggs, fish or shellfish
Take one capsule four times daily with food, or as directed by a qualified health practitioner.
Consult a health care practitioner prior to use if you are pregnant, breastfeeding, if you have diabetes, cystinuria, heart disease or cancer, or if you are taking blood pressure medication, blood thinners, nitroglycerin or antibiotics. Consult a health care practitioner for use beyond six weeks. If you experience sweating, paleness, chills, headaches, dizziness and/or confusion, discontinue use and consult a health care practitioner, as these may be symptoms of serious low blood sugar. This product contains corn derived ingredients, do not use this product if you have such allergies.
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
*Contains 20 mg sodium per serving.
‡Tocotrienols: 14 mg alpha, 2 mg beta, 25 mg gamma, 7 mg delta
Non-medicinal Ingredients: rosemary extract (1 mg), silicon dioxide, sodium alginate, gum Arabic, maltodextrin, pea starch, palm oil, hydroxypropyl cellulose, sodium stearyl fumarate, acacia gum and fatty acid esters. Capsule : hypromellose.
This randomized, blinded, endpoint, placebo-controlled clinical trial with a parallel design aimed to assess the effect of three doses of tocotrienol rich vitamin E on arterial compliance, antioxidant status, aortic systolic blood pressure, serum total cholesterol, and low-density lipoprotein cholesterol (LDL-C) in healthy male adults. Participants were randomized to receive a placebo, vitamin E (80 mg per day), vitamin E (160 mg per day), or Vitamin E (320 mg per day) for two months.
The results show that all vitamin E supplemented participants were significantly different from baseline and placebo groups in plasma tocotrienol and antioxidant status. At these doses and duration of the study, no significant differences were observed in relation to the cardiovascular markers.
This randomized, double-blind, placebo-controlled, and cross-over study evaluated the effect of oral administration of alpha-lipoic acid on oxidative parameters in healthy participants exposed to muscle-damaging exercise. Healthy male participants were randomized to receive either a placebo (700 mg lactose) or alpha-lipoic acid (600 mg) daily for eight days, during which blood samples were collected before exercise, immediately after completing exercise and after 24 hours of recovery. Blood samples were assessed for total thiol concentration, reduced glutathione levels, plasma lipid peroxidation products, and more, as markers of oxidative stress. Alpha-lipoic acid supplementation increased the concentration of total thiol, increased glutathione levels while diminishing oxidative damage.
Increases in oxidative stress and inflammation contribute to many health conditions. This randomized, placebo-controlled, blinded study evaluated the effect of vitamin E, alone or in combination with alpha-lipoic acid in hemodialysis patients. Since oxidative stress, inflammation and malnutrition are commonly present in hemodialysis patients, and exacerbate the cardiovascular disease symptoms in patients with kidney diseases, the researchers hoped to reduce these risk factors in these patients. Patients were randomized to receive either a placebo, Vitamin E (400IU), alpha-lipoic acid (600 mg), or a combination of the two. They were monitored for markers of inflammation and oxidative stress, as well as subjective global assessment and body mass index.
The results show a reduction in malondialdehyde levels and C-reactive protein levels in the supplementation groups. Vitamin E supplementation, alone or in combination with alpha-lipoic acid reduced interleukin-6 levels as well. In addition, supplementation improved malnutrition status, suggesting that antioxidant supplementation could improve inflammatory and malnutrition status in hemodialysis patients with end-stage renal failure, thereby improving the quality of life of these patients.
This clinical study aimed to evaluate the effect of oxidative stress and bioenergetic status, as well as levels of endogenous coenzyme Q10 (CoQ10) on clinical symptoms of fibromyalgia. Fibromyalgia patients and healthy volunteers we assessed for clinical parameters of fibromyalgia, including the Fibromyalgia Impact Questionnaire (FIQ), visual analogs scales (VAS), and the Headache Impact Test (HIT-6). Prior to supplementation, patients with fibromyalgia had decreased levels of endogenous CoQ10, catalase, and ATP levels, as well as increased levels of lipid per in blood mononuclear cells, compared to the healthy controls. Interestingly, supplementation with CoQ10 was able to restore clinical parameters to comparable levels with healthy control levels, in addition to a significant improvement in clinical and headache symptoms, suggesting that the effect of CoQ10 on oxidative stress and oxidative stress-induced damage could be beneficial in dealing with clinical symptoms of fibromyalgia.
Coenzyme Q10 (CoQ10) is a well-known endogenous antioxidant that the mitochondria use for the production of energy in the electron transport chain. The highest levels can be found in the heart, liver, kidneys, and pancreas https://www.nccih.nih.gov/health/coenzyme-q10. Certain health conditions have been associated with decreased levels of CoQ10. The aim of this study was to evaluate the effect of CoQ10 in children with Autism Spectrum Disorders (ASD), a disorder believed to be exacerbated by oxidative stress. Children were given 30 and 60 mg of CoQ10, with or without supportive therapy and assessed through behavioural assessments and oxidative stress markers following three months of supplementation.
Results show that CoQ10 improved total antioxidant status and the Childhood Autism Rating Scale (CARS) scores, as well as gastrointestinal symptoms and sleep disorders in children with ASD.
Glutathione is known as one of the body’s most important and potent antioxidants. Poor diet, chronic disease, and stress or infections, as well as age, can deplete the body’s natural stores of glutathione. This pharmacokinetic and pharmacodynamic study published in 1992 aimed to evaluate whether a single dose of N-acetylcysteine (NAC) would be sufficient in correcting the deficiency of cysteine and glutathione in plasma and mononuclear cells of HIV-infected patients. Prior to and subsequent to administration of a single dose of NAC, cysteine, and glutathione levels were measured in the plasma and peripheral blood mononuclear cells of patients at different stages of infection.
At baseline, the plasma concentrations of glutathione and cysteine were significantly lower in HIV-infected patients than in healthy controls, correlating with absolute CD4 lymphocyte counts. Following the administration of NAC, there was a significant immediate increase in the concentration of cysteine and glutathione levels significantly increased four hours after administration, thereby promoting the antioxidant capacity and immune function.
This randomized, placebo-controlled, blinded clinical study aimed to compare the effect of multiple doses of Vitamin E tocotrienols to placebo and their potential effects on arterial compliance. Patients were randomized into one of four groups – placebo, 50 mg tocotrienols, 100 mg tocotrienols or 200 mg tocotrienols per day for 2 months. For the duration of the study, patients were assessed for arterial compliance, by carotid-femoral pulse wave and augmentation index. Patients were also monitored for total cholesterol and low-density lipoprotein (LDL) cholesterol before the start and at the end of the study.
The results show an improvement in pulse wave velocity in the tocotrienol supplemented group, compared to the placebo group, suggesting a role for vitamin E tocotrienols in blood pressure management.
A similar study looking at arterial compliance, blood pressure, lipid levels, and total antioxidant status showed similar results, with an improvement in arterial compliance and a significant decrease in systolic blood pressure levels, following supplementation with 80 mg, 160 mg or 320 mg vitamin E tocotrienols, for 2 months. The results were dose-dependent, with the 320 mg supplemented group having a more significant response, compared to the other treatment groups or the placebo. All vitamin E participants also have a significant increase in total antioxidant status, compared to the placebo group.
The aim of this randomized, placebo-controlled clinical study was to evaluate the effects of vitamin E supplementation on the risk of venous thromboembolism (VTE). This study included 39,876 women, aged 45 years or older, who were randomized to receive either a placebo or 600 IU naturally sourced vitamin E on alternate days for long term supplementation.
Documented VTE (including deep vein thrombosis or pulmonary embolism) and unprovoked VTE (no recent surgery, trauma, or cancer diagnosis) were prospectively evaluated. During the median follow up of 10.2 years, there was a 21% hazard reduction in the vitamin E supplemented group, compared to the placebo group; in unprovoked VTE, hazard reduction was 27%. In subgroup analyses, the 3% of participants who reported VTE before randomization had a 44% hazard reduction, whereas women without prior VTE had an 18% hazard reduction in the vitamin E supplemented group. Women with either factor V Leiden or the prothrombin mutation had a 49% hazard reduction associated with vitamin E treatment, all suggesting that vitamin E supplementation may reduce the risk of VTE in women, with and without prior genetic predisposition.
This randomized, double-blinded, placebo-controlled trial aimed to investigate the effect of CoQ10 on cardiovascular disease (CVD) risk factors in patients with dyslipidemia. Patients not taking any conventional treatments for hypoglycemia or hypolipidemia were randomized to receive either a placebo or CoQ10 (120 mg) per day for 24 weeks while being measured for lipid and glycemic profiles, biomarkers of inflammation and antioxidant capacity at regular intervals.
Results show a decrease in both systolic and diastolic blood pressure, with an increase in total antioxidant capacity at the 12-week mark and a further improvement in these measures at the end of the study. in addition, at the 24-week mark, there was a reduction in triglyceride levels and low-density lipoprotein (LDL) cholesterol levels, suggesting that CoQ10 may help in reducing some of the risk factors associated with CVD.
This randomized double-blind placebo-controlled 2×2 factorial intervention study aimed to assess the effects of CoQ10 supplementation on blood pressure and glycemic control in patients with type 2 diabetes mellitus (T2DM). Participants were randomized to one of four groups – group one: CoQ10 (200 mg twice daily); group two: Fenofibrate (200 mg each morning); group three: a combination of both CoQ10 and Fenofibrate; group four: no treatment or supplementation – for 12 weeks. Each participant was monitored for the effects of supplementation or treatment on blood pressure, long-term glycemic control, and oxidative stress.
In comparison to fenofibrate, CoQ10 significantly decreased both systolic and diastolic blood pressure, indicating that CoQ10 supplementation can help manage risk factors for cardiovascular disease in patients with T2DM.
This randomized, placebo-controlled, double-blind clinical study was aimed at investigating whether CoQ10 supplementation played a role in the improvement of endothelial function in patients with ischaemic left ventricular systolic function, as a marker of coronary heart disease. Patients received either a placebo or CoQ10 (300 mg) daily for 8 weeks. During the study, patients were assessed for brachial flow-mediated dilation (FMD), mitochondrial function, and other markers of cardiovascular health, oxidative stress, and inflammation.
Following supplementation, the researchers found a reduction in lactate/pyruvate ratio, which corresponded to an improvement in FMD, suggesting an improvement in mitochondrial and endothelial function.
A similar study, with 200 mg CoQ10 daily for 12 weeks, in comparison to a placebo, showed similar activity in improving the endothelial function of the conduit arteries of the peripheral circulation in dyslipidaemic patients with Type II diabetes. The activity of CoQ10 is believed to be based on the activity of nitric oxide due to the improvement in vascular oxidative stress.
This systematic review and meta-analysis of 13 randomized controlled clinical trials reviewed the evidence for the effect of vitamin C supplementation on low density (LDL) and high-density (HDL) lipoprotein cholesterols and triglycerides in patients with hypercholesterolemia. Participants were administered a minimum daily dose of 500 mg vitamin C for a duration between three and 24 weeks. The results showed a significant effect of vitamin C supplementation on LDL cholesterol levels. Administration for a minimum of four weeks was associated with a significant decrease in LDL cholesterol and triglyceride concentrations, showing the benefit of vitamin C in cardiovascular health.
This balanced, randomized, controlled trial evaluated the effect of alpha-lipoic acid on cardiovascular disease risk in obese participants with impaired glucose tolerance. Participants were randomly assigned to one of two experimental groups. Subjects in group one completed a 12-week control phase during which habitual dietary intake and physical activity were monitored and maintained at consistent levels, followed by 12 weeks of chronic exercise for 30 minutes a day, five days per week while ingesting 1 g of racemic α-lipoic acid per day for 12 weeks. Participants in group two completed a 12-week control phase, followed by 12 weeks of 1 g per day of racemic α-lipoic acid supplementation.
Results show that combining α-lipoic acid with exercise saw an attenuation of LDL oxidation while increasing total antioxidant capacity
This study aimed to evaluate the role of oxidative stress and dysregulation of antioxidant function in diabetic complications, and the effect, if any, of antioxidant supplementation. The supplementation in this study included Coenzyme Q10 (60 mg), Vitamin E tocopherols (200 mg), and alpha-lipoic acid (100 mg) daily for three months, along with polarized light applications.
The results show that the addition of polarized light further increased the plasma concentrations of the antioxidants. In addition, supplementation with these antioxidants decreased plasma peroxides, decreased lactate dehydrogenase activity, and contributed to an improvement in heart left ventricular function in diabetic patients.
This systematic review and meta-analysis aimed to review randomized, controlled clinical trials looking at the effect of alpha-lipoic acid on the metabolic status of patients with strokes since strokes tend to have comorbid metabolic abnormalities. The criteria included patients with stroke and comorbid issues surrounding blood glucose and increased lipid profiles. Five studies were included in the meta-analysis and the results show that ALA supplementation significantly reduced fasting glucose levels in patients with stroke, with no significant observed in the lipid profiles of the patients, confirming the blood glucose reducing the effect of ALA.
This randomized double-blind placebo-controlled clinical trial aimed to assess the effect of alpha-lipoic acid (DL) on glycemic and oxidative status in patients with type II diabetes mellitus (T2DM). Patients were randomized into one of five groups – placebo, 300 mg ALA, 600 mg ALA, 900 mg ALA, or 1200 mg ALA per day – for six months. All participants were evaluated for glucose status and oxidative biomarkers for the duration of the study. The results show a dose-dependent decrease in glycated hemoglobin (HbA1c), a marker of blood sugar levels. ALA supplementation also decreased urinary levels of PGF2α-Isoprostanes (F2α-IsoP), suggesting that ALA reduced lipid peroxidation in T2DM patients. These results show the health benefits of ALA are related to its antioxidant and blood sugar reducing properties. https://pubmed.ncbi.nlm.nih.gov/22374556/
The aim of this double-blind, placebo-controlled, randomized clinical trial was to evaluate the effect of vitamin E tocotrienol supplementation on immune responses, following tetanus toxoid vaccine challenge in healthy female volunteers. Participants were randomized to receive either a placebo or 400 mg vitamin E tocotrienols per day for two months; during the course of the study, participants were assessed at baseline, 28 days and 56 days into the study.
Vitamin E supplementation enhanced the production of interferon-γ (IFN-γ) and interleukin (IL)-4, compared to the placebo control group. These participants also had lower levels of IL-6 and immunoglobulin G production was enhanced in the Vitamin E supplemented group, suggesting that vitamin E supplementation has immunostimulatory properties that enhance immune responses to vaccination.
The effect of vitamin E supplementation on immune response in healthy older adults was assessed in this randomized, double-blind, placebo-controlled clinical trial. Participants received either a placebo or 800 mg Vitamin E daily for a month. Each participant was assessed for plasma tocopherol content, delayed-type hypersensitivity skin test (DTH), as well as markers of inflammation, immunity, and oxidative stress before and after supplementation.
As expected, plasma levels of alpha-tocopherol were higher in the supplemented group, compared to the placebo group. More importantly, the results show that short-term supplementation improves immune responsiveness in healthy participants and this property is mediated by a decrease in prostaglandin E2 and other lipid peroxidation products.
Several studies suggest that vitamin E supplementation may improve immune responses, especially in elderly people. The aim of this multicenter, randomized, double-blind, placebo-controlled clinical trial was to determine the effect of a year-long supplementation of vitamin E on respiratory tract infections in elderly participants. 617 participants, aged 65 years or older, were randomized to receive either placebo or vitamin E (200 IU) per day for a year and were monitored for the incidence of respiratory tract infections, a number of days of infections, and a number of prescriptions filled out for infections.
The results show, although there was no significant effect on lower respiratory tract infections, the effect on upper respiratory tract infections was more significant. There were fewer participants in the vitamin E supplemented group that acquired one or more respiratory tract infections. The vitamin E supplemented group had a lower incidence of the common cold and a general protective effect on other upper respiratory tract infections, compared to the placebo group.
Pneumonia is a common lung infection that is responsible for many deaths annually. It is commonly co-indicated with many other infections and conditions, so safe preventative or effective therapies are of utmost importance. This systematic review and meta-analysis of published randomized, controlled clinical trials were carried out to assess the evidence for the prophylactic and therapeutic effects of vitamin C in patients with pneumonia. To assess the therapeutic effects of vitamin C, we selected placebo‐controlled trials. To assess prophylactic effects, we selected controlled trials with or without a placebo.
Three prophylactic trials were included in this analysis and all three found a statistically significant reduction in the incidence of pneumonia in the vitamin C group, compared to placebo groups. Two therapeutic trials were included in the analysis, with results showing lower mortality and reduced severity of illness in the vitamin C group, in a dose-dependent manner, compared to the control groups.
Customers also bought
You may also like…
Advanced Magnesium Complex®
Maximum magnesium benefits from four bioavailable forms
- The most advanced magnesium supplement available
- Contains four bioavailable forms of magnesium, each with its own unique benefits
- Enhances energy production, mood and sleep
- Supports muscle function, bone health, and heart health
- Supports DNA
- Optimizes vitamin D status